Announced
Completed
Synopsis
GreatPoint Ventures, an early-stage venture capital investment firm, led a $60m funding round in Excision BioTherapeutics, a developer of potentially curative CRISPR anti-viral therapies to improve patient lives. "Over 38m people live with HIV and more than 250m live with Hepatitis B around the world. We are hopeful that Excision’s technology has the potential to eradicate these, as well as other diseases including PML and Herpes Virus," Vasudev Bailey, ARTIS Ventures Senior Partner.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.